C4 Therapeutics, Inc.
CCCCDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CCCC Earnings Report
EPS Est: $-0.23 | FQ end 2026-06
How CCCC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cemsidomide | Phase 2 | Multiple Myeloma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in C4 Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in C4 Therapeutics, Inc.'s (CCCC) pipeline across Phase 2. Its lead program is Cemsidomide (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is C4 Therapeutics, Inc.'s next FDA catalyst?→
C4 Therapeutics, Inc.'s (CCCC) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CCCC biotech catalysts?→
Add CCCC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow C4 Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.